Clinical trials: GC/GEJC
HER2-positive Gastric Cancer
Adjuvant Treatment With Serplulimab，Trastuzumab and SOX in the HER-2 Positive GC/GEJC
This is a prospective, single arm, multicenter phase II study to assess the effectiveness of Serplulimab，Trastuzumab and SOX in the adjuvant treatment of HER-2 Positive Gastric/Gastroesophageal Junction Carcinoma (GC/GEJC)
- Trial name
- NCT06439550
- Testing
- Serplulimab, Trastuzumab, Oxaliplatin + Tegafur
- Volunteers
- 42 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Gastroesophageal Junction Adenocarcinoma, Stomach Neoplasms
Phase II Study of Avelumab Plus Chemotherapy in the Peri-operative Treatment for Patients With Resectable Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJC)
Phase II Study of Avelumab plus chemotherapy in the peri-operative treatment for patients with resectable Gastric cancer (GC) or Gastroesphageal Junction cancer (GEJC) The addition of Avelumab to the perioperative chemotherapy in…
- Trial name
- MONEO (NCT03979131)
- Testing
- Avelumab addition to perioperative chemotherapy in GC and GEJC
- Where
- Spain
- Volunteers
- 40 people
- Sponsor
- Vall d'Hebron Institute of Oncology
Gastric Cancer
Tislelizumab Plus Chemotherapy as Postoperative Adjuvant Therapy in Elderly Patients With LA GC/GEJC
The purpose of study is to evaluate the efficacy and safety of postoperative adjuvant chemotherapy with tislelizumab in combination with tegafur-gimeracil-oteracil potassium (S-1 therapy) or tegafur-gimeracil-oteracil potassium +…
- Trial name
- NCT06238167
- Testing
- Tislelizumab, S-1 therapy, low dose SOX therapy
- Volunteers
- 40 people
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University
NSCLC (Advanced Non-small Cell Lung Cancer), Colorectal Cancer
Allogeneic NK Cell Therapy Combined With Standard Maintenance Treatment in Advanced Solid Tumors
This is a prospective, open-label, exploratory clinical study to evaluate the safety and preliminary efficacy of allogeneic natural killer (NK) cell injection combined with standard maintenance therapy in patients with locally…
- Conditions
- NSCLC (Advanced Non-small Cell Lung Cancer), Colorectal Cancer, Advanced Solid Tumors, Advanced Hepatocellular Carcinoma (HCC)
- Trial name
- NCT07551778
- Testing
- NK Cells, NK cells + PD-(L)1 inhibitor + pemetrexed as first-line maintenance therapy, NK cells + cetuximab/bevacizumab + capecitabine as first-line maintenance therapy
- Volunteers
- 42 people
- Sponsor
- BOE Technology Group Co., Ltd.
Gastric Cancer, Microsatellite Instability
TremelImumab aNd Durvalumab For the Non-operatIve Management (NOM) of MSI-high Resectable GC/GEJC.
INFINITY is a Phase II, multicentre, single-arm, multi-cohort trial aimed at evaluating the activity and safety of the combination of tremelimumab and durvalumab as neoadjuvant (Cohort 1) and definitive (Cohort 2) treatment for…
- Trial name
- INFINITY (NCT04817826)
- Testing
- Durvalumab, Tremelimumab
- Where
- Italy
- Volunteers
- 31 people
- Sponsor
- Gruppo Oncologico del Nord-Ovest
GC/GEJC
Mecapegfilgrastim Combined With Adebrelimab and Chemotherapy as Neoadjuvant Therapy in Resectable GC/GEJC
This study is a prospective, randomized ，multicencter, phase II clinical trial that aims to enroll patients with locally advanced gastric adenocarcinoma who have not received any prior treatment and are candidates for surgery.
- Trial name
- NCT06684158
- Testing
- Mecapegfilgrastim, Adebrelimab, Docetaxel
- Where
- China
- Volunteers
- 70 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
GC, GEJC
Trastuzumab Combined With Retlirafusp Alfa in Treating HER2（Human Epidermal Growth Factor Receptor 2） 2+/3+ Gastric/Gastroesophageal Junction Adenocarcinoma After First-line Systemic Therapy Failure
Using a prospective, exploratory trial design, we aim to evaluate the efficacy and safety of RC-Trastuzumab combined with Rilafup Alpha in treating first-line systemically treated HER2（Human Epidermal Growth Factor Receptor 2 ）…
- Trial name
- NCT07817654
- Testing
- Trastuzumab Rezetecan+Retlirafusp alfa
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Henan Cancer Hospital
Gastric Cancer
Cadonilimab Plus CapeOX as First-Line Treatment for Advanced GC/GEJC With High TMEscore
This is a single-arm, open-label, multi-center clinical study to evaluate the efficacy and safety of PD-1/CTLA-4 bispecific cadonilimab in combination with oxaliplatin/capecitabine (CapeOX) in the first-line treatment of advanced…
- Trial name
- NCT06202716
- Testing
- Cadonilimab plus CapeOX chemotherapy
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Gastric Cancer
Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC
This is a study for participants with advanced gastric or gastroesophageal junction adenocarcinoma who have had tumor progression after first-line platinum-contained therapy.
- Trial name
- NCT04342910
- Testing
- camrelizumab, Apatinib Mesylate, Paclitaxel
- Where
- China
- Volunteers
- 550 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Gastric Cancer
Lenvatinib Plus Tislelizumab and CapeOX as First-Line Treatment for Advanced GC/GEJC With Positive PD-L1 and Low TMEscore
This is a multicenter, prospective, phase II clinical study to evaluate the efficacy and safety of intensive treatment with lenvatinib plus tislelizumab and CapeOX as first-line treatment for advanced gastric cancer or…
- Trial name
- NCT06157996
- Testing
- lenvatinib and tislelizumab plus CapeOX chemotherapy, tislelizumab plus CapeOX chemotherapy
- Where
- China
- Volunteers
- 92 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Advanced Gastric Cancer, Advanced Gastroesophageal Junction Adenocarcinoma
Tislelizumab Combined With S-1 Plus Oxaliplatin as a Neoadjuvant Treatment in Patients With GC/GEJC
At present, the treatment of advanced gastric/gastroesophageal junction cancer is a research hotspot in the academic community. In Asia, Siewert type II and type III are the main types of advanced gastric/gastroesophageal…
- Trial name
- NCT04890392
- Testing
- PD-1 inhibitor(Tislelizumab) ,SOX(S-1+ Oxaliplatin)
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
GC/GEJC
Phase Ib/IIa Open-label Study, to Evaluate Safety, Tolerability, and Antitumor Activity of HCB101 in Combination With Multiple Agents in Subjects With Advanced Gastric or Gastro-esophageal (GEJ) Adenocarcinoma
This is an open-label, dose-escalation and dose-expansion phase Ib/IIa clinical study to evaluate the safety, tolerability, and preliminary efficacy of HCB101 in combination therapies in subjects with gastric or GEJ…
- Trial name
- HCB101 GC GEJ (NCT07680569)
- Testing
- Zolbetuximab, Oxaliplatin + 5-Fluorouracil/Leucovorin, CAPOX (oxaliplatin/capecitabine)
- Volunteers
- 40 people
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Advanced Solid Tumor
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
This study will evaluate the safety, efficacy, optimal dose, and pharmacokinetics (PK) of BNT326 as monotherapy (Part 1) and as combination treatment with immunotherapeutic agents (Part 2) in participants with histologically or…
- Trial name
- NCT07070232
- Testing
- BNT326, Pumitamig, Itraconazole
- Where
- 77 sites in United States, Australia and 7 more
- Volunteers
- 1,438 people
- Sponsor
- BioNTech SE
Adebrelimab (SHR-1316), XELOX
A Phase II Trial of Perioperative Adebrelimab Combined With XELOX in Resectable Locally Advanced Gastric/Gastroesophageal Junction Cancer (GC/GEJC)
To observe and evaluate the efficacy and safety of adebrelimab combination chemotherapy regimen in the perioperative treatment of surgically resectable gastric cancer/adenocarcinoma of the gastroesophageal junction.
- Conditions
- Adebrelimab (SHR-1316), XELOX, GC/GEJC
- Trial name
- NCT06506292
- Testing
- Adebrelimab, XELOX
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
GC/GEJC
A Random, Non-controlled, Open Clinical Study of Apatinib Mesylate Combined With Albumin-bound Paclitaxel ± Adebrelimab in Treating Advanced Second-line Gastric Cancer
This study is a prospective, randomized, non-controlled, open-label clinical trial aimed at evaluating the efficacy and safety of adebrelimab combined with apatinib mesylate and albumin-bound paclitaxel, as well as apatinib…
- Trial name
- NCT07770113
- Testing
- Adebrelimab, Apatinib, Albumin-bound paclitaxel
- Where
- China
- Volunteers
- 50 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Gastric, Esophagogastric Junction
A Study of Neoadjuvant-adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in Chinese Patients With Resectable GC/GEJC.
This study aims to assess the efficacy and safety of neoadjuvant adjuvant treatment with durvalumab in combination with FLOT compared to placebo in combination with FLOT in Chinese patients with Resectable Gastric and…
- Trial name
- NCT07877818
- Testing
- FLOT Chemotherapy, Durvalumab
- Volunteers
- 140 people
- Sponsor
- AstraZeneca
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatment
This trial is a registrational Phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-M05D1 in patients with Claudin (CLDN) 18.2-positive advanced gastric cancer or gastroesophageal…
- Trial name
- NCT07518147
- Testing
- BL-M05D1, Paclitaxel, Docetaxel
- Where
- China
- Volunteers
- 438 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Gastric (Stomach) Cancer
XELOX Combined With Sintilimab and HBO for Advanced or Metastatic GC/GEJC
This study investigates the efficacy and safety of XELOX chemotherapy combined with sintilimab and hyperbaric oxygen therapy (HBOT) as a first-line treatment for patients with Advanced or Metastatic gastric and gastroesophageal…
- Trial name
- NCT06742411
- Testing
- XELOX+Sintilimab+HBOT
- Where
- 2 sites in China
- Volunteers
- 57 people
- Sponsor
- West China Hospital
ESCC, Gastric Adenocarcinoma
Sacituzumab Tirumotecan (Sac-TMT/SKB264) Plus Tagitanlimab (KL-A167) in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma
This is a single-arm, multi-center phase II study to evaluate the efficacy and safety of sacituzumab tirumotecan (Sac-TMT/SKB264) combined with tagitanlimab (KL-A167) as 2nd line therapy for recurrent or metastatic esophageal…
- Conditions
- ESCC, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Squamous Cell Carcinoma (ESCC)
- Trial name
- NCT07701681
- Testing
- Sacituzumab Tirumotecan + Tagitanlimab
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Sun Yat-sen University
GC/GEJC
Disitamab Vedotin Combined With SOX Regimen Versus SOX Alone as Adjuvant Therapy for HER2-Moderate/High Expressing Stage Ⅲ Gastric Cancer: A Prospective, Multicenter, Randomized, Phase Ⅱ Clinical Trial
This is a prospective, multicenter, randomized, phase II clinical trial intended to enroll patients with HER2-moderate/high-expressing, pathologically staged stage III gastric cancer who have undergone D2 or more extensive…
- Trial name
- NCT07474324
- Testing
- RC48, SOX Chemotherapy, SOX(normal)
- Where
- China
- Volunteers
- 124 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University